Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review

被引：13
|
作者：
Stiefel, Hillary C. [1 ,2 ]
Kopplin, Laura J. [1 ,2 ,3 ]
Albini, Thomas [4 ]
Chang, Michael [1 ,5 ]
Vegunta, Sravanthi [4 ,6 ]
Suhler, Eric B. [1 ,2 ]
机构：
[1] Portland VA Hlth Care Syst, Dept Ophthalmol, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA
[3] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Oregon Hlth & Sci Univ, Hosp & Specialty Med, Portland, OR 97201 USA
[6] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA
来源：
OCULAR IMMUNOLOGY AND INFLAMMATION | 2021年 / 29卷 / 03期
基金：
美国国家卫生研究院;
关键词：
Pegylated interferon (peginterferon alfa-2A); uveitis; cystoid macular edema; CHRONIC HEPATITIS-C; UVEITIS; THERAPY; EFFICACY;
D O I：
10.1080/09273948.2019.1687729
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in CME in all eyes of seven included patients, with a mean decrease in CMT from 478 mu m to 310 mu m (p < .05). The vision in one patient did not improve due to preexisting retinal atrophy. All other eyes showed improvement in vision, with a mean improvement in best LogMAR visual acuity from +0.59 to +0.28 (p < .05). The treatment effect was sustained with low-dose treatment every 2 weeks or less in the majority of patients. Two patients who stopped interferon treatment given flu-like symptoms and intolerable rash, respectively, showed rapid recurrence of CME. Conclusions: Weekly administration of pegylated interferon alfa-2A is an effective treatment for refractory inflammatory CME, though side effects may limit tolerability in some patients.
引用
收藏
页码：566 / 571
页数：6
相关论文
共 50 条
  • [31] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Nishio, Kazuaki
    Konndo, Takeshi
    Okada, Shunichi
    Enchi, Machiko
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (09) : 358 - 361
  • [32] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Kazuaki Nishio
    Takeshi Konndo
    Shunichi Okada
    Machiko Enchi
    World Journal of Hepatology, 2010, 2 (09) : 358 - 361
  • [33] Camel Milk with Pegylated Interferon Alfa-2a and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 2/3: An Open-Label, Randomized Controlled Trial
    Hosseini, Seyyd Musa al-Reza
    Zibaee, Said
    Yousefi, Mahdi
    Taghipour, Ali
    Ghanaei, Omid
    Noras, Mohammadreza
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2017, 19 (09)
  • [34] Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behcet's uveitis
    Onal, S.
    Kazokoglu, H.
    Koc, A.
    Akman, M.
    Bavbek, T.
    Direskeneli, H.
    Yavuz, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (02) : S113 - S114
  • [35] Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behcet Disease Uveitis
    Albayrak, Ozgur
    Oray, Merih
    Can, Fusun
    Kirimli, Gunay Uludag
    Gul, Ahmet
    Tugal-Tutkun, Ilknur
    Onal, Sumru
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (01) : 52 - 63
  • [36] Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review
    Calvo-Rio, Vanesa
    Blanco, Ricardo
    Santos-Gomez, Montserrat
    Diaz-Valle, David
    Pato, Esperanza
    Loricera, Javier
    Gonzalez-Vela, Maria C.
    Demetrio-Pablo, Rosalia
    Hernandez, Jose L.
    Gonzalez-Gay, Miguel A.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (05) : 609 - 614
  • [37] A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer
    Sunela, Kaisa Leea
    Koskinen, Sanna
    Kellokumpu-Lehtinen, Pirkko-Liisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 59 - 67
  • [38] Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Manshouri, Taghi
    Luthra, Rajyalakshmi
    Estrov, Zeev
    Pierce, Sherry
    Richie, Mary Ann
    Borthakur, Gautam
    Konopleva, Marina
    Cortes, Jorge
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5418 - 5424
  • [39] Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
    Marcellin, Patrick
    Wursthorn, Karsten
    Wedemeyer, Heiner
    Chuang, Wan-Long
    Lau, George
    Avila, Claudio
    Peng, Cheng-Yuan
    Gane, Edward
    Lim, Seng Gee
    Fainboim, Hugo
    Foster, Graham R.
    Safadi, Rifaat
    Rizzetto, Mario
    Manns, Michael
    Bao, Weibin
    Trylesinski, Aldo
    Naoumov, Nikolai
    JOURNAL OF HEPATOLOGY, 2015, 62 (01) : 41 - 47
  • [40] The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
    Wei, Xin
    Fan, Chao
    Zhou, Yun
    Kang, Wenzhen
    Wang, Jiuping
    Sun, Li
    Wang, Linxu
    Peng, Meijuan
    Lian, Jianqi
    Jia, Zhansheng
    Hao, Chunqiu
    HEPATITIS MONTHLY, 2016, 16 (01)
12345